Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 4
  5. Article
Volume 23, Issue 4
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

Co-occurrence of substance use disorders is frequent in patients with mental health disorders is a condition known as “dual diagnosis”. The use of substances worsens the prognosis and lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and suicide rate.

Objectives

To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes in dually diagnosed patients.

Methods

We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and Web of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually diagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates (n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.

Results

12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent psychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol and cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement after aripiprazole treatment. 8 studies evaluated craving and found a significant reduction after treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and maintenance of abstinence.

Conclusion

The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X23666241023115252
2024-10-24
2025-03-30

  • From This Site

    /content/journals/cn/10.2174/1570159X23666241023115252
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KhokharJ.Y. DwielL.L. HenricksA.M. DoucetteW.T. GreenA.I. The link between schizophrenia and substance use disorder: A unifying hypothesis.Schizophr. Res.2018194788510.1016/j.schres.2017.04.016 28416205
     [Google Scholar]
  2. EdwardK.L. RobinsA. Dual diagnosis, as described by those who experience the disorder: Using the Internet as a source of data.Int. J. Ment. Health Nurs.201221655055910.1111/j.1447‑0349.2012.00833.x 22830579
     [Google Scholar]
  3. HuntG.E. MalhiG.S. LaiH.M.X. ClearyM. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic review and meta-analysis.J. Affect. Disord.202026628830410.1016/j.jad.2020.01.141 32056890
     [Google Scholar]
  4. SullivanL.E. FiellinD.A. O’ConnorP.G. The prevalence and impact of alcohol problems in major depression: A systematic review.Am. J. Med.2005118433034110.1016/j.amjmed.2005.01.007 15808128
     [Google Scholar]
  5. BlancoC. AlegríaA.A. LiuS.M. Secades-VillaR. SugayaL. DaviesC. NunesE.V. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions.J. Clin. Psychiatry201273686587310.4088/JCP.10m06673 22480900
     [Google Scholar]
  6. VorspanF. MehtelliW. DupuyG. BlochV. LépineJ.P. Anxiety and substance use disorders: Co-occurrence and clinical issues.Curr. Psychiatry Rep.2015172410.1007/s11920‑014‑0544‑y 25617040
     [Google Scholar]
  7. ClayS. AllenJ. ParranT. A review of addiction.Postgrad. Med.20081202E01E0710.3810/pgm.2008.07.1802 18654058
     [Google Scholar]
  8. JonesC.A. WatsonD.J.G. FoneK.C.F. Animal models of schizophrenia.Br. J. Pharmacol.201116441162119410.1111/j.1476‑5381.2011.01386.x 21449915
     [Google Scholar]
  9. TrostS. DiekhofE.K. ZvonikK. LewandowskiM. UsherJ. KeilM. ZillesD. FalkaiP. DechentP. GruberO. Disturbed anterior prefrontal control of the mesolimbic reward system and increased impulsivity in bipolar disorder.Neuropsychopharmacology20143981914192310.1038/npp.2014.39 24535101
     [Google Scholar]
  10. SpanoM.C. LorussoM. PettorrusoM. ZorattoF. Di GiudaD. MartinottiG. GiannantonioM. Anhedonia across borders: Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes.CNS Neurosci. Ther.201925111229123610.1111/cns.13230 31638332
     [Google Scholar]
  11. MurthyP. ChandP. Treatment of dual diagnosis disorders.Curr. Opin. Psychiatry201225319420010.1097/YCO.0b013e328351a3e0 22395768
     [Google Scholar]
  12. StahlS.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors.J. Clin. Psychiatry2001621184184210.4088/JCP.v62n1101 11775041
     [Google Scholar]
  13. JordanS. KoprivicaV. ChenR. TottoriK. KikuchiT. AltarC.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.Eur. J. Pharmacol.2002441313714010.1016/S0014‑2999(02)01532‑7 12063084
     [Google Scholar]
  14. CaseyA.B. CanalC.E. Classics in chemical neuroscience: Aripiprazole.ACS Chem. Neurosci.2017861135114610.1021/acschemneuro.7b00087 28368577
     [Google Scholar]
  15. RibeiroE.L.A. de Mendonça LimaT. VieiraM.E.B. StorpirtisS. AguiarP.M. Efficacy and safety of aripiprazole for the treatment of schizophrenia: An overview of systematic reviews.Eur. J. Clin. Pharmacol.201874101215123310.1007/s00228‑018‑2498‑1 29905899
     [Google Scholar]
  16. YathamL.N. KennedyS.H. ParikhS.V. SchafferA. BondD.J. FreyB.N. SharmaV. GoldsteinB.I. RejS. BeaulieuS. AldaM. MacQueenG. MilevR.V. RavindranA. O’DonovanC. McIntoshD. LamR.W. VazquezG. KapczinskiF. McIntyreR.S. KozickyJ. KanbaS. LaferB. SuppesT. CalabreseJ.R. VietaE. MalhiG. PostR.M. BerkM. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar Disord.20182029717010.1111/bdi.12609 29536616
     [Google Scholar]
  17. WobrockT. SoykaM. Pharmacotherapy of schizophrenia with comorbid substance use disorder - Reviewing the evidence and clinical recommendations.Prog. Neuropsychopharmacol. Biol. Psychiatry20083261375138510.1016/j.pnpbp.2008.02.008 18394768
     [Google Scholar]
  18. WolfM.E. Synaptic mechanisms underlying persistent cocaine craving.Nat. Rev. Neurosci.201617635136510.1038/nrn.2016.39 27150400
     [Google Scholar]
  19. MartinottiG. De RisioL. VanniniC. SchifanoF. PettorrusoM. Di GiannantonioM. Substance-related exogenous psychosis: A postmodern syndrome.CNS Spectr.2021261849110.1017/S1092852920001479 32580808
     [Google Scholar]
  20. WangS. Historical review: Opiate addiction and opioid receptors.Cell Transplant.201928323323810.1177/0963689718811060 30419763
     [Google Scholar]
  21. LiX. CaprioliD. MarchantN.J. Recent updates on incubation of drug craving: A mini-review.Addict. Biol.201520587287610.1111/adb.12205 25440081
     [Google Scholar]
  22. KalivasP.W. VolkowN.D. The neural basis of addiction: A pathology of motivation and choice.Am. J. Psychiatry200516281403141310.1176/appi.ajp.162.8.1403 16055761
     [Google Scholar]
  23. GrodinE.N. CourtneyK.E. RayL.A. Drug-induced craving for methamphetamine is associated with neural methamphetamine cue reactivity.J. Stud. Alcohol Drugs201980224525110.15288/jsad.2019.80.245 31014470
     [Google Scholar]
  24. VolkowN.D. BoyleM. Neuroscience of addiction: Relevance to prevention and treatment.Am. J. Psychiatry2018175872974010.1176/appi.ajp.2018.17101174 29690790
     [Google Scholar]
  25. PribiagH. ShinS. WangE.H.J. SunF. DattaP. OkamotoA. GussH. JainA. WangX.Y. De FreitasB. HonmaP. PateS. LilascharoenV. LiY. LimB.K. Ventral pallidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking.Neuron20211091321652182.e1010.1016/j.neuron.2021.05.002 34048697
     [Google Scholar]
  26. BeresfordT. BuchananJ. ThummE.B. EmrickC. WeitzenkampD. RonanP.J. Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs. perphenazine in schizophrenia and comorbid cocaine dependence.J. Clin. Psychopharmacol.201737665766310.1097/JCP.0000000000000789 28984746
     [Google Scholar]
  27. CuomoI. KotzalidisG.D. de PersisS. PiacentinoD. PerriniF. AmiciE. De FilippisS. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life.Neuropsychiatr. Dis. Treat.2018141645165610.2147/NDT.S171002 29950846
     [Google Scholar]
  28. FarniaV. ShakeriJ. TatariF. JuibariT.A. YazdchiK. BajoghliH. BrandS. AbdoliN. AghaeiA. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis.Am. J. Drug Alcohol Abuse2014401101510.3109/00952990.2013.861843 24359506
     [Google Scholar]
  29. Hyun HanD. Mi KimS. Eun ChoiJ. Joon MinK. RenshawmP.F. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence Doug.Physiol. Behav.20171761213914810.1177/0269881112472563.Adjunctive
     [Google Scholar]
  30. SulaimanA.H. GillJ.S. SaidM.A. ZainalN.Z. HusseinH.M. GuanN.C. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis.Int. J. Psychiatry Clin. Pract.201317213113810.3109/13651501.2012.667116 22486597
     [Google Scholar]
  31. SkryabinV.Y. VinnikovaM.A. EzhkovaE.V. TitkovM.S. BulatovaR.A. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: The results of a randomized comparative study.J. Addict. Dis.202139451352510.1080/10550887.2021.1905589 33832406
     [Google Scholar]
  32. BeresfordT.P. ClappL. MartinB. WibergJ.L. AlfersJ. BeresfordH.F. Aripiprazole in schizophrenia with cocaine dependence: A pilot study.J. Clin. Psychopharmacol.200525436336610.1097/01.jcp.0000169419.38899.5b 16012280
     [Google Scholar]
  33. BrunoA. RomeoV.M. PandolfoG. ScimecaG. ZoccaliR.A. MuscatelloM.R.A. Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: An 8-week, open-label, uncontrolled, preliminary study.Subst. Abus.201435211912110.1080/08897077.2013.814615 24821345
     [Google Scholar]
  34. McRae-ClarkA.L. VerduinM.L. TolliverB.K. CarterR.E. WahlquistA.E. BradyK.T. CluverJ.S. AndersonS. An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy.J. Dual Diagn.200951839610.1080/15504260802620210
     [Google Scholar]
  35. BrownE.S. JeffressJ. LigginJ.D.M. GarzaM. BeardL. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole.J. Clin. Psychiatry200566675676010.4088/JCP.v66n0613 15960570
     [Google Scholar]
  36. SzermanN. Basurte-VillamorI. VegaP. Martinez-RagaJ. Parro-TorresC. Cambra AlmergeJ. Grau-LópezL. De MatteisM. AriasF. Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring] substance use disorders: A multicentre, observational study.Drugs Real World Outcomes202071758310.1007/s40801‑020‑00178‑8 32026379
     [Google Scholar]
  37. MartinottiG. NicolaM.D. JaniriL. Efficacy and safety of aripiprazole in alcohol dependence.Am. J. Drug Alcohol Abuse200733339340110.1080/00952990701313660 17613966
     [Google Scholar]
  38. HanD.H. KimS.M. ChoiJ.E. MinK.J. RenshawP.F. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence.J. Psychopharmacol.201327328229110.1177/0269881112472563 23325372
     [Google Scholar]
  39. McRae-ClarkA.L. Efficacy and safety of aripiprazole in alcohol dependence.Drugs Real World Outcomes202071839610.2147/NDT.S171002
     [Google Scholar]
  40. SinhaR. The clinical neurobiology of drug craving.Curr. Opin. Neurobiol.201323464965410.1016/j.conb.2013.05.001 23764204
     [Google Scholar]
  41. KoobG.F. Le MoalM. SeV. Neurobiological mechanisms for opponent motivational processes in addiction. 2008; pp. 3113312310.1098/rstb.2008.0094
     [Google Scholar]
  42. CaineS.B. NegusS.S. MelloN.K. PatelS. BristowL. KulagowskiJ. ValloneD. SaiardiA. BorrelliE. Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists.J. Neurosci.20022272977298810.1523/JNEUROSCI.22‑07‑02977.2002 11923462
     [Google Scholar]
  43. MiuliA. PettorrusoM. RomanelliE. StiglianoG. Di GiudaD. De-GiorgioF. MartinottiG. di GiannantonioM. Does DRD2 Taq1A mediate aripiprazole-induced gambling disorder? a pharmacogenetic hypothesis.Front. Psychiatry20201127510.3389/fpsyt.2020.00275 32351415
     [Google Scholar]
  44. VorelS.R. AshbyC.R.Jr PaulM. LiuX. HayesR. HaganJ.J. MiddlemissD.N. StempG. GardnerE.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.J. Neurosci.200222219595960310.1523/JNEUROSCI.22‑21‑09595.2002 12417684
     [Google Scholar]
  45. WolfschlagM. HåkanssonA. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden.PLoS One2021166e025251610.1371/journal.pone.0252516 34061895
     [Google Scholar]
  46. PettorrusoM. ZorattoF. MiuliA. De RisioL. SantorelliM. PierottiA. MartinottiG. AdrianiW. di GiannantonioM. Exploring dopaminergic transmission in gambling addiction: A systematic translational review.Neurosci. Biobehav. Rev.202011948151110.1016/j.neubiorev.2020.09.034 33035523
     [Google Scholar]
  47. CorrellC.U. The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence.J. Clin. Psychiatry201677suppl 312410.4088/JCP.15032su1
     [Google Scholar]
  48. MisawaF. KishimotoT. HagiK. KaneJ.M. CorrellC.U. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.Schizophr. Res.20161762-322023010.1016/j.schres.2016.07.018 27499361
     [Google Scholar]
  49. ColesA.S. KnezevicD. GeorgeT.P. CorrellC.U. KaneJ.M. CastleD. Long-acting injectable antipsychotic treatment in schizophrenia and co-occurring substance use disorders: A systematic review.Front. Psychiatry20211280800210.3389/fpsyt.2021.808002 34975600
     [Google Scholar]
/content/journals/cn/10.2174/1570159X23666241023115252
Loading
Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review
Curr. Neuropharmacol. 23, 404 (2025); https://doi.org/10.2174/1570159X23666241023115252
/content/journals/cn/10.2174/1570159X23666241023115252
/content/journals/cn/10.2174/1570159X23666241023115252
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): aripiprazole; bipolar disorder; craving; dual disorder; Schizophrenia; substance use disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test